Steven Katz, M.D.

Steven Katz, M.D.

Chief Medical OfficeratTriSalus Life Sciences· In proxies 2022–2023

Pay in FY2023+102% from the year before · TriSalus Life Sciences stock -15.8% the same year

Steven Katz, M.D. was paid $1.6M in FY2023 (Dec), up 102%. TriSalus Life Sciences stock fell 15.8% that year.

Pay$100 in the stock at the end of FY21 → $86
Pay is from the Summary Compensation Table of each TriSalus Life Sciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. TriSalus Life SciencesPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role -60%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?